Tirzepatide versus CPAP for sleep apnoea
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study compares a new medication, tirzepatide, to CPAP (a breathing machine used during sleep) to see which is better at treating obstructive sleep apnoea in people who are overweight. If you qualify, you will receive one of these treatments to help improve your breathing and sleep.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate to severe obstructive sleep apnoea (diagnosed by a sleep study in the last 12 months, with a respiratory event index of 15 or more per hour)
- Your body mass index (BMI) is 27 or higher (or 25 or higher if you are of Asian descent)
- You have not been treated for sleep apnoea with CPAP or similar devices in the last 3 months
- You do not have diabetes or take medication for blood sugar control
- You have internet access at home
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This trial tests if the weight loss medication tirzepatide can help young adults (18–40) with obesity and high blood pressure lower their blood pressure. It compares standard care to weight loss with tirzepatide.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.